Investors
Anaveon is backed by more than 146 million CHF (€140 million) of funding, enabling us to develop cytokine based therapies that have the potential to save patients’ lives.
Our funding includes a 150 thousand CHF award from BaseLaunch, a 1 million CHF convertible loan from University of Zurich Life Sciences Fund and 35 million CHF in Series A funding led by Syncona and joined by the Novartis Venture Fund.
In 2022, Anaveon secured a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax.